LISATA THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
LISATA THERAPEUTICS, INC. (LSTA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$4.71 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2019-03-14
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-12-31 was -$1.07M, a 105.85% decline year-over-year.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-09-30 was -$4.29M.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-06-30 was $1.84M, a 93.21% decline year-over-year.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$1.19M.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was -$4.71M, a 111.35% decline from fiscal 2017.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $41.46M.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$1.10M.
- LISATA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$10.74M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$5.36M derived: sum of 2 quarters · filed 2019-03-14 | -$3.52M derived: sum of 3 quarters · filed 2019-03-14 | -$4.71M 10-K · filed 2019-03-14 | |
| 2018-09-30 | -$4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$2.45M derived: sum of 2 quarters · filed 2018-11-08 | -$3.64M 10-Q · filed 2018-11-08 | $14.59M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2018-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $650.32K 10-Q · filed 2018-08-09 | $18.89M derived: sum of 3 quarters · filed 2019-03-14 | $15.09M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2018-03-31 | -$1.19M 10-Q · filed 2018-05-10 | $17.05M derived: sum of 2 quarters · filed 2019-03-14 | $13.25M derived: sum of 3 quarters · filed 2019-03-14 | $40.34M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2017-12-31 | $18.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $14.44M derived: sum of 2 quarters · filed 2019-03-14 | $41.53M derived: sum of 3 quarters · filed 2019-03-14 | $41.46M 10-K · filed 2019-03-14 | $41.46M 10-K · filed 2018-03-22 |
| 2017-09-30 | -$3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $23.29M derived: sum of 2 quarters · filed 2018-11-08 | $23.22M 10-Q · filed 2018-11-08 | $23.19M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-06-30 | $27.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $27.02M 10-Q · filed 2018-08-09 | $26.99M derived: sum of 3 quarters · filed 2018-08-09 | $26.99M derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | -$69.65K 10-Q · filed 2018-05-10 | -$100.98K derived: sum of 2 quarters · filed 2018-05-10 | -$100.98K derived: sum of 3 quarters · filed 2018-05-10 | ||
| 2016-12-31 | -$31.33K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | -$31.33K derived: sum of 2 quarters · filed 2018-03-22 | -$1.10M 10-K · filed 2018-03-22 | ||
| 2016-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$1.07M 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | -$1.07M 10-Q · filed 2017-08-10 | ||||
| 2014-12-31 | -$10.74M 10-K · filed 2015-03-02 | ||||
| 2013-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$2.42M derived: sum of 2 quarters · filed 2015-03-02 | -$2.64M derived: sum of 3 quarters · filed 2015-03-02 | -$2.69M 10-K · filed 2015-03-02 | |
| 2013-09-30 | -$680.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$895.07K derived: sum of 2 quarters · filed 2013-11-07 | -$948.64K 10-Q · filed 2013-11-07 | $8.27M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | -$214.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$268.54K 10-Q · filed 2013-08-08 | $8.95M derived: sum of 3 quarters · filed 2015-03-02 | $11.66M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | -$53.57K 10-Q · filed 2013-05-09 | $9.16M derived: sum of 2 quarters · filed 2015-03-02 | $11.87M derived: sum of 3 quarters · filed 2015-03-02 | $11.83M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | $9.22M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $11.92M derived: sum of 2 quarters · filed 2015-03-02 | $11.88M derived: sum of 3 quarters · filed 2015-03-02 | $11.75M 10-K · filed 2015-03-02 | |
| 2012-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $2.66M derived: sum of 2 quarters · filed 2013-11-07 | $2.53M 10-Q · filed 2013-11-07 | $2.56M derived: sum of 4 quarters · filed 2013-11-07 | |
| 2012-06-30 | -$44.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$176.01K 10-Q · filed 2013-08-08 | -$147.82K derived: sum of 3 quarters · filed 2013-08-08 | -$266.94K derived: sum of 4 quarters · filed 2013-08-08 | |
| 2012-03-31 | -$131.97K 10-Q · filed 2013-05-09 | -$103.78K derived: sum of 2 quarters · filed 2013-05-09 | -$222.91K derived: sum of 3 quarters · filed 2013-05-09 | ||
| 2011-12-31 | $28.20K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | -$90.93K derived: sum of 2 quarters · filed 2013-03-11 | -$251.40K 10-K · filed 2013-03-11 | ||
| 2011-09-30 | -$119.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | -$279.59K 10-Q · filed 2012-11-13 | |||
| 2011-06-30 | -$160.47K 10-Q · filed 2012-08-14 | ||||
| 2010-12-31 | -$3.60M 8-K · filed 2012-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |